| Abstrakt: |
A study conducted by researchers at Navy Medical University in Shanghai, China, investigated the potential use of Troxerutin (TRX) as a treatment for jellyfish dermatitis. The researchers found that TRX inhibited the major signaling pathways responsible for inducing inflammation and oxidative damage in jellyfish dermatitis. By activating the Nrf2/HO-1 signaling pathway, TRX suppressed the phosphorylation of MAPK and NF-kB, resulting in a decrease in inflammatory cytokine release. These findings suggest that TRX could be a novel therapy for jellyfish dermatitis. [Extracted from the article] |
